Bionano Laboratories Sees 47% Increase in 2026 CLFS for OGM Testing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Should l Buy BNGO?
Source: Newsfilter
- Fee Increase: Bionano Laboratories' CPT code 81195 sees a 47% increase in the 2026 Clinical Laboratory Fee Schedule, rising from $1,263.53 to $1,853.22, which will significantly enhance reimbursement for OGM testing related to blood cancers, thereby strengthening market competitiveness.
- Committee Support: The Clinical Diagnostic Laboratory Test Committee unanimously voted 10-0 in favor of reconsidering the payment standard for CPT code 81195, indicating strong industry recognition and confidence in OGM technology.
- Market Impact: The new pricing is expected to make Bionano's OGM-Dx™ product line more attractive, likely driving market share growth in hematologic malignancy testing and further solidifying its leadership position in genome analysis.
- Global Recognition: Bionano's Chief Medical Officer stated that the new payment level will not only facilitate the promotion of OGM testing in the U.S. market but also enhance global awareness of OGM applications in oncology and clinical genetic testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BNGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BNGO
Wall Street analysts forecast BNGO stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.160
Low
7.00
Averages
7.50
High
8.00
Current: 1.160
Low
7.00
Averages
7.50
High
8.00
About BNGO
Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bionano Genomics 2025 Financial Report Analysis
- Revenue Decline: Bionano Genomics reported Q4 2025 revenue of $8 million, down 3% year-over-year, indicating a decline in sales performance, with total revenue for 2025 at $28.5 million, a 7% decrease reflecting a challenging market environment.
- Margin Improvement: The company achieved a non-GAAP gross margin of 47% for the full year 2025, up from 35% in 2024, indicating significant progress in operational efficiency that may enhance future profitability.
- Cost Management Success: Non-GAAP operating expenses were reduced to $36.6 million in 2025, down 47% year-over-year, showcasing effective cost control measures that strengthen the company's financial health.
- OGM Systems Exceed Guidance: The installation of 32 OGM systems in 2025 surpassed the original guidance of 15 to 20, reflecting increasing market acceptance and demand for its technology.
See More
Bionano Genomics Q4 2025 Earnings Call Insights
- Strategic Shift: Bionano Genomics initiated a strategic shift in September 2024, focusing on profitable growth from high-volume users rather than aggressive installed base expansion, aiming to enhance profitability through increased utilization and reimbursement support for existing users.
- Financial Performance: Q4 2025 revenue was $8 million, down 3% from Q4 2024, yet within the pre-announced range, with a non-GAAP gross margin rising to 43%, reflecting effective cost control and product quality improvements.
- Future Outlook: The company projects 2026 revenue between $30 million and $33 million, representing 5% to 16% growth, emphasizing that the increase in CPT code pricing will serve as a significant revenue growth catalyst.
- Supply Chain Challenges: Although Q4 sales were impacted by supply chain constraints for consumables, management expects these issues to resolve in the coming quarters, thereby supporting growth in consumable sales.
See More
Bionano Genomics (BNGO) Earnings Transcript
See More
Financial Analysis of Bionano Genomics
- Financial Overview: Bionano Genomics' financial information indicates that despite facing market challenges, the company is striving to maintain a stable revenue stream, reflecting its ongoing commitment to investment and R&D in the genomics field.
- Historical Earnings Trends: Historical earnings data shows that Bionano Genomics' revenue has remained relatively stable over the past few quarters, indicating the company's competitiveness and stability in its customer base within the market.
- Market Outlook Analysis: Although current financial performance is modest, the growth potential in the genomics market presents future opportunities for Bionano Genomics, particularly in precision medicine and personalized treatment sectors.
- Investor Focus: Investors should monitor Bionano Genomics' financial health and progress in technological innovation to assess its long-term investment value and market positioning.
See More
Bionano Genomics Reports Q4 Earnings with Mixed Results
- Financial Overview: Bionano Genomics reported a net loss of $8 million in Q4 2025, while revenue of $8 million, down 2.4% year-over-year, exceeded market expectations by $120,000, indicating some revenue resilience amid challenges.
- Sales Data Analysis: The company sold 7,554 nanochannel array flowcells in Q4, a 6% decrease from 8,058 units sold in Q4 2024, reflecting weakened market demand that could pose challenges for future revenue growth.
- Future Revenue Guidance: Bionano initiated Q1 2026 revenue guidance in the range of $6.5 million to $6.7 million, below the consensus estimate of $7.15 million, indicating a cautious outlook that may affect investor confidence.
- Annual Outlook: The company set full-year 2026 revenue guidance between $30 million and $33 million, also below the consensus of $34.55 million, raising concerns about its long-term growth potential in the eyes of investors.
See More
Bionano Genomics Projects FY Revenue Between $30 Million and $33 Million
- Revenue Overview: The biotechnology company BioNano Genomics has reported a revenue of USD 30-33 million.
- Market Outlook: The financial outlook indicates potential growth and expansion in the genomics sector.
See More
Bionano Genomics 2025 Financial Report Analysis
- Revenue Decline: Bionano Genomics reported Q4 2025 revenue of $8 million, down 3% year-over-year, indicating a decline in sales performance, with total revenue for 2025 at $28.5 million, a 7% decrease reflecting a challenging market environment.
- Margin Improvement: The company achieved a non-GAAP gross margin of 47% for the full year 2025, up from 35% in 2024, indicating significant progress in operational efficiency that may enhance future profitability.
- Cost Management Success: Non-GAAP operating expenses were reduced to $36.6 million in 2025, down 47% year-over-year, showcasing effective cost control measures that strengthen the company's financial health.
- OGM Systems Exceed Guidance: The installation of 32 OGM systems in 2025 surpassed the original guidance of 15 to 20, reflecting increasing market acceptance and demand for its technology.
See More
Bionano Genomics Q4 2025 Earnings Call Insights
- Strategic Shift: Bionano Genomics initiated a strategic shift in September 2024, focusing on profitable growth from high-volume users rather than aggressive installed base expansion, aiming to enhance profitability through increased utilization and reimbursement support for existing users.
- Financial Performance: Q4 2025 revenue was $8 million, down 3% from Q4 2024, yet within the pre-announced range, with a non-GAAP gross margin rising to 43%, reflecting effective cost control and product quality improvements.
- Future Outlook: The company projects 2026 revenue between $30 million and $33 million, representing 5% to 16% growth, emphasizing that the increase in CPT code pricing will serve as a significant revenue growth catalyst.
- Supply Chain Challenges: Although Q4 sales were impacted by supply chain constraints for consumables, management expects these issues to resolve in the coming quarters, thereby supporting growth in consumable sales.
See More
Bionano Genomics (BNGO) Earnings Transcript
See More
Financial Analysis of Bionano Genomics
- Financial Overview: Bionano Genomics' financial information indicates that despite facing market challenges, the company is striving to maintain a stable revenue stream, reflecting its ongoing commitment to investment and R&D in the genomics field.
- Historical Earnings Trends: Historical earnings data shows that Bionano Genomics' revenue has remained relatively stable over the past few quarters, indicating the company's competitiveness and stability in its customer base within the market.
- Market Outlook Analysis: Although current financial performance is modest, the growth potential in the genomics market presents future opportunities for Bionano Genomics, particularly in precision medicine and personalized treatment sectors.
- Investor Focus: Investors should monitor Bionano Genomics' financial health and progress in technological innovation to assess its long-term investment value and market positioning.
See More
Bionano Genomics Reports Q4 Earnings with Mixed Results
- Financial Overview: Bionano Genomics reported a net loss of $8 million in Q4 2025, while revenue of $8 million, down 2.4% year-over-year, exceeded market expectations by $120,000, indicating some revenue resilience amid challenges.
- Sales Data Analysis: The company sold 7,554 nanochannel array flowcells in Q4, a 6% decrease from 8,058 units sold in Q4 2024, reflecting weakened market demand that could pose challenges for future revenue growth.
- Future Revenue Guidance: Bionano initiated Q1 2026 revenue guidance in the range of $6.5 million to $6.7 million, below the consensus estimate of $7.15 million, indicating a cautious outlook that may affect investor confidence.
- Annual Outlook: The company set full-year 2026 revenue guidance between $30 million and $33 million, also below the consensus of $34.55 million, raising concerns about its long-term growth potential in the eyes of investors.
See More
Bionano Genomics Projects FY Revenue Between $30 Million and $33 Million
- Revenue Overview: The biotechnology company BioNano Genomics has reported a revenue of USD 30-33 million.
- Market Outlook: The financial outlook indicates potential growth and expansion in the genomics sector.
See More
